Semaglutide for use in medicine
AssigneeNovo Nordisk A/S
InventorsMartin Linder, Mads Sundby Palle, Lars Holm Damgaard
Life of this patent
Estimating the term…
Abstract
The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
Claims28
A method of treating non-alcoholic steatohepatitis (NASH), comprising administrating semaglutide in an amount in the range of about 0.7 to about 5 mg per week to a subject diagnosed with NASH.
(canceled)
(canceled)
-12. (canceled)
A method of treating non-alcoholic steatohepatitis (NASH), comprising administrating an effective amount of semaglutide to a subject diagnosed with NASH, wherein the subject has liver fibrosis stage 2 or liver fibrosis stage 3, wherein the liver fibrosis stage is classified according to the Kleiner fibrosis classification, and wherein the semaglutide is administered in an amount in the range of about 0.7 to about 5 mg per week.
-23. (canceled)
-27. (canceled)
Dependencies are inferred from the claim text.